Accès ouvert

Epigallocatechin-3-gallate (EGCG) as a Potential Therapeutic Against Cardiovascular Disease Risk in Mice

Article scientifique 2022 Anglais

Résumé

Abstract Objective: Research is focused on cardiovascular disease (CVD). CVD is the leading cause of death in the world and remains one of the major diseases strongly affected by diet and sedentary lifestyle. The aim of this study was to determine the potential effect of EGCG on blood lipid and glucose profiles in mice exposed to conditions that lead to CVD. Groups of male mice were subjected to different diet, exercise and EGCG supplementation. EGCG was delivered in drinking water for a dose of 30 mg /kg/ day. Blood was collected for lipid and glucose analysis. The data was analyzed using a mulit variate approach including one-way analysis of variance test (one-way ANOVA), Tukey –Kramer multiple comparison test and pairwise correlation analysis was used to determine the significance between control and treated groups.Results: The mice subjected to high-fat diet (Anova p-value = 0.0039) and sedentary lifestyle (Anova p-value = 0.0016) showed elevated levels for total cholesterol, LDL cholesterol triglycerides and glucose. EGCG supplementation in mice undergoing high fat diet and sedentary lifestyle resulted in a significant reduction in the lipid profiles and blood glucose (Anova p-value = 0.0001).

Citer ce document

Banzubaze, E., Mulindwa, J., Ochwo, S., Wampande, E. (2022). Epigallocatechin-3-gallate (EGCG) as a Potential Therapeutic Against Cardiovascular Disease Risk in Mice. https://doi.org/10.21203/rs.3.rs-1275676/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Emmanuel Banzubaze Julius Mulindwa Silver Ochwo Eddie M. Wampande

Statistiques

Consultations : 1

Téléchargements : 0